Advertisement

Pituitary Tumors in Oncology

  • Ian E. McCutcheon
Part of the M. D. Anderson Cancer Care Series book series (MDCCS)

Keywords

Pituitary Adenoma Pituitary Gland Pituitary Tumor Cavernous Sinus Transsphenoidal Surgery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Asa SL. Tumors of the Pituitary Gland. Washington, DC: Armed Forces Institute of Pathology; 1998.Google Scholar
  2. Biswas M, Smith J, Jadon D, et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol 2005;63:26–31.CrossRefGoogle Scholar
  3. Bohinski RJ, Warnick RE, Gaskill-Shipley MF, et al. Intraoperative magnetic resonance imaging to determine the extent of resection of pituitary macroadenomas during transsphenoidal microsurgery. Neurosurgery 2001;49:1133–1143.PubMedCrossRefGoogle Scholar
  4. Brada M, Ajithkumar TV, Minniti G. Radiosurgery for pituitary adenomas. Clin Endocrinol 2004;61:531–543.CrossRefGoogle Scholar
  5. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004;101:613–619.PubMedCrossRefGoogle Scholar
  6. Hamilton DK, Vance ML, Boulos PT, Laws ER. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 2005;8:53–60.PubMedCrossRefGoogle Scholar
  7. Hardy J. Transsphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg 1969;16:185–217.PubMedGoogle Scholar
  8. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999;2:29–41.PubMedCrossRefGoogle Scholar
  9. Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer? Clin Endocrinol 2006;64:115–121.CrossRefGoogle Scholar
  10. Kaltsas GA, Mukherjee JJ, Plowman PN, Monson JP, Grossman AB, Besser GM. The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab 1998;83:4233–4238.PubMedCrossRefGoogle Scholar
  11. Komninos J, Vlassopoulou V, Protopapa D, et al. Tumors metastatic to the pituitary gland: case report and literature review. J Clin Endocrinol Metab 2004;89: 574–589.PubMedCrossRefGoogle Scholar
  12. Landolt AM, Haller D, Lomax N, et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg 1998;88:1002–1008.PubMedCrossRefGoogle Scholar
  13. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc 2005; 80:1050–1057.PubMedCrossRefGoogle Scholar
  14. Mountcastle RB, Roof BS, Mayfield RK, et al. Pituitary adenocarcinoma in an acromegalic patient: response to bromocriptine and pituitary testing: a review of the literature on 36 cases of pituitary carcinoma. Am J Med Sci 1989;298: 109–118.PubMedCrossRefGoogle Scholar
  15. Nieman LK, Ilias I. Evaluation and treatment of Cushing's syndrome. Am J Med 2005;118:1340–1346.PubMedCrossRefGoogle Scholar
  16. Nilsson B, Gustavasson-Kadaka E, Bengtsson BA, Jonsson B. Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. J Clin Endocrinol Metab 2000;85:1420–1425.PubMedCrossRefGoogle Scholar
  17. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol 2005;152:379–387.PubMedCrossRefGoogle Scholar
  18. Oberg K. Future aspects of somatostatin receptor-mediated therapy. Neuroendocrinology 2004;80:57–61.PubMedCrossRefGoogle Scholar
  19. Park P, Chandler WF, Barkan AL, et al. The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery 2004;55: 100–106.PubMedCrossRefGoogle Scholar
  20. Pereira AM, van Alken MO, van Dulken H, et al. Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing's disease. J Clin Endocrinol Metab 2003;88:5858–5864.PubMedCrossRefGoogle Scholar
  21. Prabhu SS, Aldape KD, Gagel RF, Benjamin RS, Trent JC, McCutcheon IE. Sarcomatous change in a growth hormone-secreting pituitary adenoma: possible influence by IGF-I. Can J Neurol Sci 2003;30:378–383.PubMedGoogle Scholar
  22. Randeva HS, Schoebel J, Byrne J, Esiri M, Adams CB, Wass JA. Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol 1999;51: 181–188.CrossRefGoogle Scholar
  23. Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT, Young WF Jr, Lloyd RV. Pituitary carcinoma: a clinicopathological review. Neurosurgery 2005;56: 1066–1074.PubMedGoogle Scholar
  24. Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989;68:412–418.PubMedCrossRefGoogle Scholar
  25. Selman W, Laws ER, Scheithauer BW, Carpenter SM. The occurrence of dural invasion in pituitary adenomas. J Neurosurg 1986;64:402–407.PubMedCrossRefGoogle Scholar
  26. Socin HV, Chanson P, Delemer B, et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol 2003;148:433–442.PubMedCrossRefGoogle Scholar
  27. Tischler RB, Loeffler JS, Lunsford LD, et al. Tolerance of cranial nerves of the cavernous sinus to radiosurgery. Int J Radiat Oncol Biol Phys 1993;27:215–221.Google Scholar
  28. Toogood A. Safety and efficacy of growth hormone replacement therapy in adults. Expert Opin Drug Saf 2005;4:1069–1082.PubMedCrossRefGoogle Scholar
  29. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone receptor antagonist pegvisomant. N Engl J Med 2000;342: 1171–1177.PubMedCrossRefGoogle Scholar
  30. Tyrrell JB, Lamborn KR, Hannegan LT, et al. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery 1999;44:254–261.PubMedCrossRefGoogle Scholar
  31. Verges B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 Multicenter Study. J Clin Endocrinol Metab 2002;87:457–465.PubMedCrossRefGoogle Scholar
  32. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999;84:2518–2522.PubMedCrossRefGoogle Scholar
  33. Watson JC, Stratakis CA, Bryant-Greenwood PK, et al. Neurosurgical implications of Carney complex. J Neurosurg 2000;92:413–418.PubMedCrossRefGoogle Scholar
  34. Webb SM, Rigla M, Wagner A, Oliver B, Bartumeus F. Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas. J Clin Endocrinol Metab 1999;84:3696–3700.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Ian E. McCutcheon
    • 1
  1. 1.Department of NeurosurgeryThe University of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations